**Application Form Full Submission Phase**

***TKI LSH Programme FORESIGHT***

***Call for public-private partnerships 2025***

**Instructions**

For the full application, please fill all the sections below. In some section you can add the text used in the pre-proposal. You can use the Appendix H “Checklist Application Form” as reference to ensure all necessary sections have been completed.

Please also consult the appendixes for additional definitions on:

1. Definition of enterprise
2. Definition of Small and Medium Size company (SME)
3. Conflict of interest
4. Definitions Type of research
5. Definitions of Technology Readiness Levels (TRL)
6. Template Letter of Commitment
7. Checklist Application Form
8. Guidance Documents
9. Example of Ineligible costs

**In order to fit with the aims of the Foresight program, please review the list of focus points and eligibility criteria listed in page 2.**

If you have any question on this document, please contact: foresight@umcg.nl

**The FORESIGHT Evaluation Criteria for the full application:**

* The work plan is worked out sufficiently, including timeline, milestones, and deliverables. The work packages are clearly linked and well-aligned with each other.
* The project's risks have been properly assessed, and adequate consideration has been given to how these risks will be dealt with.
* The project's budget is realistic (including the number of man-hours per organization, realistic costs of materials and equipment, and realistic "costs due to third parties").
* It is clear when the project can be labeled "successful" and what criteria are used to define this.
* The planned activities to further develop, disseminate, and implement the results from the proposed research (TRL9) are well thought out and described for the partners.
* Data are properly handled within the project.
* The project aligns well with the Knowledge and Innovation Agenda 2024-2027 of the Top Sector Life Sciences & Health, and herewith, the contributions to the missions are well substantiated.
* The projects well aligns with the aims and objectives of the FORESIGHT program and contributes to one of more of the expected FORESIGHT outputs.

**Criteria and points specific to the FORESIGHT program**

Admissible full project proposals will be assessed and scored with a checklist. The template contains all questions to assess whether you have met TKI-LSH eligibility requirements, including financial requirements.

**General Health Holland requirements for PPPs**

* The research fits within the social theme 'Health & Care,' the Central Mission, and one of the five focused Missions, as described in the [Knowledge and Innovation Agenda (KIA) 2024-2027](https://www.health-holland.com/en/publications/useful-documents/kia) of Top Sector LSH. (see Appendix H).
* The consortium must consist of at least one research organization and a private partner.
* The project has a maximum duration of 4 years.
* The project consists of industrial research, experimental development, or a combination thereof (TRL 4 – 7). Projects at lower TRL levels (TRL<4, fundamental research) can apply but have a lower chance of being awarded.
* Effective collaboration takes place. The project is executed with joint efforts, costs, and risks - all consortium partners contribute substantially.
* All consortium partners should make an in-kind contribution. This means, for example, but not limited to, all consortium partners must incur payroll costs and that these costs are visible in the budget form. A list of not eligible costs is provided in Appendix I.
* A collaboration agreement using the template approved by Health~Holland and the consortium partners should be signed by the start of the project.

**FORESIGHT specific criteria/advices**

* A link with a member of the FORESIGHT core module or disease area teams and at least a private and a public partner.
* Collaboration with companies in the Netherlands or internationally, SMEs, and public partners, such as healthcare providers, patients, and insurers.
* The project should be carried out within the FORESIGHT Innovation and Service Center.
* Contribution to FORESIGHT objectives and appropriate output. We aim to have most of awarded project proposals with TRL ≥4. Technology readiness level: The Development phase (TRL 4, 5, 6), The Demonstration phase (TRL 7 & 8)
* An innovative public-private R&D project in drug development or choice with molecular imaging in one of the four disease areas, using one or more modules.
* Duration preferably 3 to a maximum of 4 years.
	+ Note that for the use of the available PPS subsidy for 2025 (under the Health Holland Program period 1 January 2025-31 December 2030), projects must be concluded at latest by 30 September 2030. This means that, the latest starting dates of projects are:
		- For 4-year projects: 1 October 2026
		- For 3-year projects: 1 October 2027
		- For 2-year projects: 1 October 2028
* Dissemination to the scientific community and the wider public.
* Social impact well substantiated.
* Economic impact well substantiated.
* Good quality, partly in view of feasibility and mitigation plan.
* Maximum project budget of ~€1,500,000, of which €750,000 is a subsidy, 50% contribution by public-private parties, of which cash contribution is at least 10% for large companies.
* Collaborations with Dutch SMEs are encouraged.

|  |
| --- |
| **A. Registration** |

**1A. Project title:**

**1B. Project acronym (if applicable):**

**2. Contact details of main applicant (project coordinator)**

*If applicable, list all co-applicants from an organisation under the same consortium partner in the designated table.*

|  |
| --- |
| **Consortium partner 1** |
| Name of the organisation |  |
| Department |  |
| Name of contact person, title(s) |  |
| Male/female/other |  |
| Position |  |
| Address for correspondence |  |
| Telephone |  |
| E-mail: |  |
| Type of organisation (for enterprise definition see Appendix A) | [ ]  Research organisation[ ]  For profit enterprise[ ]  Non-for-profit enterprise[ ]  Health fund[ ]  Other, namely:  |
| SME (MKB)* Type of SME

(for SME definition see Appendix B) | [ ]  Yes à [ ]  Micro [ ]  Small [ ]  Medium[ ]  No[ ]  NA |
| Chamber of commerce number or equivalent |  |
| URL of own web page |  |

|  |
| --- |
| **Co-applicants from the same organisation as consortium partner 1** |
| Department | Name of contact person, title(s) |
|  |  |

**3. List of consortium partners (co-applicants)[[1]](#footnote-2)**

|  |
| --- |
| **Consortium partner 2** |
| Name of the organisation |  |
| Department |  |
| Name of contact person, title(s) |  |
| Address for correspondence |  |
| E-mail: |  |
| Type of organisation(for enterprise definition see Appendix A) | [ ]  Research organisation[ ]  For profit enterprise[ ]  Non-for-profit enterprise[ ]  Health fund[ ]  Other, namely: |
| SME (MKB)* Type of SME

(for SME definition see Appendix B) | [ ]  Yes à [ ]  Micro [ ]  Small [ ]  Medium[ ]  No[ ]  NA  |
| Chamber of commerce number or equivalent |  |
| URL of own web page |  |

|  |
| --- |
| **Co-applicants from the same organisation as consortium partner 2** |
| Department | Name of contact person, title(s) |
|  |  |

|  |
| --- |
| **Consortium partner 3** |
| Name of the organisation |  |
| Department |  |
| Name of contact person, title(s) |  |
| Address for correspondence |  |
| E-mail: |  |
| Type of organisation(for enterprise definition see Appendix A) | [ ]  Research organisation[ ]  For profit enterprise[ ]  Non-for-profit enterprise[ ]  Health fund[ ]  Other, namely: |
| SME (MKB)* Type of SME

(for SME definition see Appendix B) | [ ]  Yes à [ ]  Micro [ ]  Small [ ]  Medium[ ]  No[ ]  NA |
| Chamber of commerce number or equivalent |  |
| URL of own web page |  |

|  |
| --- |
| **Co-applicants from the same organisation as consortium partner 3** |
| Department | Name of contact person, title(s) |
|  |  |

Etc.

**4. Potential conflict of interest**

*Please specify if there are any potential conflict of interests for individual scientists or any of the consortium partner organisations. See Appendix C for more information on conflict of interest. If there is a potential conflict of interest please also indicate how the consortium will manage such conflict.*

**5. Consortium agreement and IP**

*The mandatory consortium agreement template can be downloaded from our* [***FORESIGHT webpage***](https://umcgresearch.org/w/foresight-ppp-program)*Describe any amendments the consortium has made. In addition, describe the reasoning behind these amendments.*

*Note: The deadline for the signed consortium agreement is* ***1st February 2026.***

**6. Start date (dd-mm-yyyy):**

*Note: for the Final start date**please check the dates indicated at page 2*

**7. End date (dd-mm-yyyy):**

*Note: Final end date is before 30 September 2030*

**8. Duration of the project (max.48 months):**

|  |
| --- |
| 1. **Project overview**
 |

**Fill in the word count:**

**9A. Project summary (max. 300 words)**

*Describe the background, objective, design, and relevance of the project.*

**9B. Public summary in Dutch**

**Fill in the word count:**

**(max. 300 words, in lay language)**

*Describe the background, objective, design, and relevance of the project.*

**Fill in the word count:**

**9C. Impact summary (max. 300 words)**

*Describe the expected short- and long-term societal impact (1), economic impact (2) and scientific impact (3) of the project.*

**9D. Keywords (max. 5)**

**10. Research category (see Appendix D)**

1. *Please indicate per work package the budget and the applicable type(s) of research (more than one option possible); if more than one type of research is applicable for the work package, please indicate the relative contribution of each category to the WP budget.*

|  |  |  |
| --- | --- | --- |
| **WP** | % of total budget (WP budget/total budget \* 100%) | **Type of Research** |
| Fundamental research | Industrial Research | Experimental Development |
| 1 | … % | … % | … % | … % |
| 2 | … % | … % | … % | … % |
| Etc. | … % | … % | … % | … % |

1. *Provide an explanation for the research type(s) chosen. Use the phrasing provided in the definition of the three types of research (see Appendix D).*

|  |
| --- |
| **B. Project description** |

**Fill in the word count:**

**1. Background (max. 350 words)**

*Describe the project background and topic. Include citations and list the relevant references under question B.8 “References”.*

**2. State-of-the-art (max 250 words)**

**Fill in the word count:**

*Describe the current state-of-the-art in the field. Include a description of how the project expands on this state-of-the-art.*

**3. Objective and hypothesis (max 200 words)**

**Fill in the word count:**

*Describe the objective of the project. Clearly state the hypothesis that follows.*

Objective of the project:

Hypothesis of the project:

**4. Outline per work package****(max. 2500 words in total)**

**Fill in the word count:**

1. *Outline the work plan per work package (if more than one). Include a table or scheme, that describes the following (at a minimum): aim, time schedule, milestones and deliverables. Indicate the role and responsibilities of the applicants in the activities.*
2. *Describe the coherence between the work packages (if more than one). Include a figure to clarify the coherence.*
3. *List the total number of milestones and deliverables of the (total) project by checking the correct box. In addition, provide a table or scheme of the time schedule of the listed milestones and deliverables in each work package.*

Number of milestones:
[ ] 1 [ ] 2 [ ] 3 [ ] 4 [ ] 5 [ ] 6 [ ] 7 [ ] 8 [ ] 9 [ ] 10 [ ] More, namely:

Number of deliverables:
[ ] 1 [ ] 2 [ ] 3 [ ] 4 [ ] 5 [ ] 6 [ ] 7 [ ] 8 [ ] 9 [ ] 10 [ ] More, namely:

Time schedule:

**5. Success criteria**

1. *Describe the criteria that are utilized to determine success, the criteria should be written according to the SMART-principles (Specific, Measurable, Achievable, Realistic, and Timely) whenever possible, for:*
* *Each individual work package (if more than one)*
* *The overall project*
1. *Describe the go/no-go criteria for each of the above-described work packages*

**6. Risks & Mitigation strategies**

*Fill in the table below. Describe all risks (scientific, operational etc.) relating to the execution of the project, and for each individual WP/deliverable. Describe the mitigation strategy already incorporated in the strategy of execution or the proposed strategy adaptations once risks are encountered.*

|  |  |
| --- | --- |
| **Risk** | **Mitigation strategy** |
|  |  |
|  |  |
|  |  |
|  | Etc. |

**7. Dissemination (max. 200 words)**

**Fill in the word count:**

*Describe the activities each consortium partner plans to engage in order to promote the dissemination and implementation (including potential exploitation) of the results. This should not be limited to scientific dissemination. Include, a justification for the chosen approach for each individual consortium partner[[2]](#footnote-3).*

**8. References**

*List all authors of a reference when there are six or less; when there are seven or more authors, list the first three, then 'et al'. Avoid using the words 'in press' and ‘submitted’ in references if possible.*

|  |
| --- |
| 1. **Human subjects, laboratory animals, biological hazards**
 |

**9. Will the project involve experiments with patients or patient material?**

|  |  |
| --- | --- |
| *Patients or Patient material* | **Answer** |
| 1. Use of healthy volunteers. If yes, please provide a power calculation under this table.
 | [ ]  Yes [ ]  No |
| 1. Use of patients?
 | [ ]  Yes [ ]  No |
| 1. Number of healthy volunteers.
 |  |
| 1. Number of patients.
 |  |
| 1. Is ethical approval from a commission needed regarding experimental subjects?
 | [ ]  Yes [ ]  No [ ]  N/A |
| 1. If ‘e’ is answered with ‘yes’: Do you already have ethical approval from a commission to perform the study?
 | [ ]  Yes [ ]  No[ ]  N/A[ ]  Requested |

*Include a power calculation to justify the number of people necessary for the project:*

**10. Animal experiments**

|  |  |
| --- | --- |
| *Animal experiments* | **Answer** |
| 1. Use of laboratory animals. If yes, please fill out question 11.
 | [ ]  Yes [ ]  No |
| 1. Number of animals needed for the total project.
 |  |
| 1. Is ethical approval from a commission needed regarding experimental subjects?
 | [ ]  Yes [ ]  No [ ]  N/A |
| 1. If ‘c’ is answered with ‘yes’: do you already have ethical approval from a commission to perform the study?
 | [ ]  Yes [ ]  No[ ]  N/A[ ]  Requested |

**11. Specification and justification of animal experiments**

1. *Describe the kind of animals (species, modifications, etc.) used in the project.*
2. *Describe the nature of the animal interventions within the project.*
3. *Indicate if alternative methods (besides experimental animals) have been considered. In addition, describe whether and which experts have been consulted and whether a systematic review has been performed?*
4. *What are the reasons that this project cannot be performed without experimental animals (replacement)?*
5. *What are the reasons that this project cannot be performed with fewer animals (reduction) or with less distress and discomfort for the animals (refinement)? Include a power calculation to justify the number of animals necessary for the project.*
6. *What are the reasons that this project cannot be performed with a lower species of animals?*

**12. Biological risks**

|  |  |
| --- | --- |
| *Biological risks* | **Answer** |
| 1. Use of recombinant DNA?
 | [ ]  Yes [ ]  No |
| 1. If ‘a’ is answered with ‘yes’: provide class of recombinant DNA
 |  |
| 1. Use of radiation (wave and/or particle)?
 | [ ]  Yes [ ]  No |
| 1. Use of radioactive isotopes?
 | [ ]  Yes [ ]  No |
| 1. Use of pathogenic micro-organisms?
 | [ ]  Yes [ ]  No |
| 1. Are required grants, permits and facilities available?
 | [ ]  Yes [ ]  No [ ]  N/A |

|  |
| --- |
| **B. Data management**  |

**All data management should comply with the FAIR principles: Findable, Accessible, Interoperable, and Reusable.[[3]](#footnote-4) Applicants need to draw up a data management plan if their application is granted. The approval of the data management plan by the FORESIGHT Program Group is a condition for the disbursement of the PPP Subsidy.**

**13. Use of pre-existing research data**

*Is it possible to answer the research question(s) using existing data and a pre-existing research methodology? If not, or only partially, please explain the added value of the new data and/or methodology to existing datasets.*

**14. Reuse of collected data**

*Please elaborate whether data will be collected or generated that is suitable for reuse by other parties. If not, explain why the project will not result in reusable data, or data that cannot be stored, or data that is not relevant for reuse for other reasons (please explain the reasoning).*

|  |
| --- |
| 1. **Impact**
 |

**Fill in the word count:**

**1. Scientific impact (max. 200 words)**

*Describe the impact the project will have on the scientific field. In addition, describe how the project may benefit further research and other research groups within the field.*

**2. Societal impact (max. 200 words)**

**Fill in the word count:**

*Describe the expected impact the project will have on society and the LSH sector in particular. Please include a description of the current societal problem the project (with additional follow-up projects) is aiming to solve.*

**3. Economic**

 **impact**

1. *Describe impact the project will have on the Dutch economy (e.g., the size of the market, amount of FTE generated etc.) (1). Include a cost-effectiveness analysis or value-based-reasoning analysis to support your claims (2). In addition, include a description of how the consortium fits into the current competitive environment (3) (max. 250 words).*

**Fill in the word count:**

1. *Describe the expected economic impact the project will have on each individual private party (e.g., projected launch date, projected revenues, projected costs), and public/other party where relevant, involved (max. 200 words per private party).*

**Fill in the word count:**

**4. Current and expected TRL-levels**

*Indicate the current (1) and expected (2) Technology Readiness Level (TRL; see Appendix E) of the project (level of development/readiness to go to the market), and for each TRL why this is applicable for the project.*

* 1. *Current TRL:*

*[ ]* TRL 1 [ ] TRL 2 [ ] TRL 3 [ ] TRL 4 [ ] TRL 5

[ ] TRL 6 [ ] TRL 7 [ ] TRL 8 [ ] TRL 9

**Fill in the word count:**

* 1. *Description of current TRL (max. 150 words):*
	2. *Expected TRL:*

*[ ]* TRL 1 [ ] TRL 2 [ ] TRL 3 [ ] TRL 4 [ ] TRL 5

[ ] TRL 6 [ ] TRL 7 [ ] TRL 8 [ ] TRL 9

* 1. *Description of expected TRL (max. 150 words):*

**Fill in the word count:**

**Fill in the word count:**

**5. Market introduction, reaching TRL 9 (max. 200 words)**

*Describe who (1) and what (2) is needed to introduce the innovation into the market/clinic (TRL 9). If no additional parties (3) are needed to introduce the innovation to the market/clinic, describe how the consortium is planning on accomplishing this on their own.*

|  |
| --- |
| 1. **Collaboration (max. 500 words)**
 |

**1. Benefits of individual consortium partners to the project**

*Describe how and why each individual consortium partner and its applicants add value to the project. Include a description of why the consortium partners are better equipped to execute the project than other, similar parties.*

**2. Benefits of the project to consortium partners**

*Describe how each of the individual consortium partner benefits from participating in this project (1). In addition, describe how the project fits into the strategic mission of each individual consortium partner (2).*

**3. Responsibilities of consortium partners and collaboration activities**

*Describe the responsibilities of each individual consortium partner within the project. In addition, describe how the consortium plans to collaborate (communication, sharing results, progress meetings, etc.)*

|  |
| --- |
| 1. **Budget specification**
 |

**Fill in the TKI-LSH budget form. Use the version of the budget form specific for this FORESIGHT Call (2025). Other versions of the budget form will not be accepted. Examples of not eligible costs are provided in Appendix I.**

**4. Deployment of PPP Subsidy**

*Indicate for each consortium partner (1) their total costs; (2) the amount of PPP subsidy that they will use; (3) the percentage of costs that will be financed using the PPP subsidy; (4) the amount of (private) cash that they will use and (5) the activities that will be financed using the PPP subsidy.*

*Notes:*

* *Total costs include all the costs made by the partner, including the costs covered by the in kind contribution, PPP subsidy or in cash contributions to be received from another party. Own in cash contributions to the project are not included as a cost.*
* *Each consortium partner must incur payroll costs (in kind) as part of the collaboration.*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Partner** | **Total Costs** | **PPP Subsidy** | **% PPP Subsidy** | **Used cash** | **Activities** |
| ***Name Consortium Partner 1***  |  |  |  |  |  |
| ***Name Consortium Partner 2*** |  |  |  |  |  |
| ***Name Consortium Partner 3*** |  |  |  |  |  |
| **Etc.** |  |  |  |  |  |
| **Total sum\*** |  |  |  |  |  |

**\****Make sure that the above table is in accordance with the budget form, including the total sum of costs and the total sum of PPP.*

**5. Budget specification**

*Please provide a justification and specification of the costs in the budgetform per work package or deliverable. Only referring to the budget form is not sufficient.*

**6. Have the consortium partners requested/received any additional grants for this project or overlapping activities?**

**[ ] Yes** **[ ] No**

*If yes, please specify grant supplier(s), grant name(s), total amount requested/received per grant (in €) and status (applied/granted) in the TKI-LSH budget form.*

|  |
| --- |
| 1. **KIA, VWS Missions**
 |

**Fill in the word count:**

**1. VWS missions: central mission (max. 250 words)**

*Describe how the project contributes to the Central Mission of the Ministry of Health, Welfare and Sport (VWS) (below) according to the SMART principles. Consult, reference and use at least one of the aspects described in the* [*theory of change*](https://online.fliphtml5.com/gedjp/iwgv/?1725364546#p=36) *of the central mission. Include a description on how the project outcome, including the outcome of eventual follow-up projects, aids in reducing health disparities between people with high SES and low SES (1), use the* [*Key Principles to reduce health disparities*](https://www.pharos.nl/gezondheidsverschillen-duurzaam-aanpakken/) *in your answer. In addition, include a description on how, at the end of the project, the concrete contribution to the mission can be measured/evaluated.*

***Central Mission:*** *By 2040, all people in the Netherlands will live at least five years longer in good health, while the health disparities between the lowest and highest socio-economic groups will have decreased by 30%.*

*Documents and links for guidance are provided in Appendix H.*

*Argumentation (max. 250 words):*

**2. VWS missions: mission I – mission V**

**Fill in the word count:**

**(max. 300 words)**

*Describe how the project contributes to one or more of the underlying missions of the Mission of the Ministry of Health, Welfare and Sport (VWS) (below) according to the SMART principles. In addition, if the project contributes to more than one mission, indicate which of the missions the project mainly contributes to (select one).*

*Consult, reference and use at least one of the aspects described the* [*Theory of Change*](https://online.fliphtml5.com/gedjp/iwgv/#p=42)*of the missions. In addition, include a description of how, at the end of the project, the concrete contribution to the mission can be measured/evaluated.*

***Mission I:*** *By 2040, the burden of disease resulting from an unhealthy lifestyle and living environment will have decreased by 30%.*

***Mission II:*** *By 2030, the extent of care provided to people within their own living environment (rather than in health-care institutions) will be 50% more than today or such care will be provided 50% more frequently than at present.*

***Mission III:*** *By 2030, the proportion of people with a chronic disease or lifelong disability who can play an active role in society according to their wishes and capabilities will have increased by 25%.*

***Mission IV:*** *By 2030, quality of life for people with dementia will have improved by 25%.*

***Mission V:*** *By 2035, the population is better protected from socially disruptive health threats.*

*Documents and links for guidance are provided in Appendix H.*

Principal mission the project contributes to (select one):

[ ] Mission I

[ ] Mission II

[ ] Mission III

[ ] Mission IV

[ ] Mission V

Secondary mission the project contributes to (if applicable):

[ ] Mission I

[ ] Mission II

[ ] Mission III

[ ] Mission IV

[ ] Mission V

[ ] Not applicable

*Argumentation:*

|  |
| --- |
| **E. Patient/end-user participation & Inclusivity**  |

**3. Inclusivity and end-user participation**

*Inclusivity entails paying attention to diversity and differentiation of the target groups concerned, including characteristics as sex, age, socio-economic status (SES), level of education, migration, cultural background, and sexual orientation, to the extent these are relevant for the theme of the project. Documents and links for guidance are provided in Appendix H.*

* 1. *Please describe to what extent the (health) problem affects men, women and/or other relevant subgroups (max. 300 words). Describe and substantiate how the project takes into account relevant differences between people (e.g. according to sex and/or gender) in the design, execution, analyses conclusions and publication of your research. If there are no relevant differences, substantiate this*

**Fill in the word count:**

* 1. *Please describe how citizens in their role as patients, end users, clients, and/or loved ones are involved in the design, execution, and dissemination/implementation of the project (max. 200 words).*

**Fill in the word count:**

|  |
| --- |
| 1. **Evaluation of health and care innovations**
 |

**4. Innovation guidance – HI-NL Round Table Service**

*Before answering the questions below, please read [section 3.7] of the* ***FORESIGHT*** *Call 2025. Documents and links for guidance are provided in Appendix H.*

|  |  |
| --- | --- |
|  | **Answer** |
| 1. In general, is your innovation in scope of the HI-NL Round Table service? I.e. is it a MedTech innovation, falling under the MDR / IVDR?
 | [ ]  Yes[ ]  No |
| If no, please explain why: |
| 1. Did the consortium partners contact HI-NL no later than three weeks before the deadline of this Call, and has an intake meeting taken place?
 | [ ]  Yes, continue to c[ ]  No |
| If no, please explain why: |
| 1. Is the HI-NL Round Table service of added value for your consortium and project that you are applying for?

*If ‘c’ is answered with ‘yes’: The consortium can choose to enter an amount of 33,275 euros in the budget form under the heading 'costs due to third parties'.* | [ ]  Yes, continue to d[ ]  No |
| 1. What is/are your main question(s) and/or challenges to be addressed by the HI-NL Round Table service? (Multiple boxes can be checked)
 | [ ]  Claims and target population[ ]  Required (clinical) evidence [ ]  Path for CE-marking[ ]  Comparison with the current standard of care[ ]  Application and integration of innovation in the Dutch healthcare system[ ]  Reimbursement of innovation[ ]  Strategy for adoption by the market[ ]  Scale-up of your innovation[ ]  Other, namely: |

|  |
| --- |
| **F. National Technology Strategy and Growth Markets** |

**1. Key Enabling Technologies (KET’s) of the National Technology Strategy**

*Indicate to which of the* [*Key Enabling Technologies*](https://www.rijksoverheid.nl/documenten/beleidsnotas/2024/01/19/de-nationale-technologiestrategie) *of the National Technology Strategy the project applies to. Documents and links for guidance are provided in Appendix H.*

|  |  |
| --- | --- |
| **Key Enabling Technologies of the National Technology Strategy** | **yes/no** |
| Biomolecular and cell technologies | [ ] Yes [ ]  No |
| Imaging technologies | [ ] Yes [ ]  No |
| Artifical intelligence and data  | [ ] Yes [ ]  No |
| Optical systems and integrated photonics | [ ] Yes [ ]  No |
| Quantum technologies | [ ] Yes [ ]  No |
| Process technology including process intensification | [ ] Yes [ ]  No |
| Mechatronics and optomechatronics | [ ] Yes [ ]  No |
| Energy materials | [ ] Yes [ ]  No |
| Semiconductor technologies | [ ] Yes [ ]  No |
| Cybersecurity technologies | [ ] Yes [ ]  No |
| Not applicable, only relevant Growth Market | [ ] Yes |

*b. Explain how the project applies to these Key Enabling Technologies of the National Technology Strategy (max. 100 words).*

**Fill in the word count:**

**2. Growth Markets for the Netherlands**

*a. Indicate which of the* [*Growth Markets for the Netherlands*](https://www.rijksoverheid.nl/documenten/rapporten/2023/12/05/dialogic-seo-groeimarkten-voor-nederland) *the project corresponds to. The specific Growth Markets of interest are GM1 and GM5, however the other Growth Markets are also relevant.*

|  |  |
| --- | --- |
| **Growth Markets** | **yes/no** |
| GM1: Innovative and high-performance molecules in the Biotech sector | [ ] Yes [ ]  No |
| GM5: Medical technology | [ ] Yes [ ]  No |
| Other relevant Growth market: GM…. | [ ] Yes [ ]  No |
| Not applicable, only relevant KET of the NTS | [ ] Yes  |

*b. Explain how the project corresponds to this Growth Market (max. 100 words).*

**Fill in the word count:**

|  |
| --- |
| **Statement by project coordinator** |

When submitting your application, please do not forget to upload the required budget form file (Excel), letter(s) of commitment, (concept) consortium agreement and other necessary documents.

Please tick the boxes where applicable:

[ ]  By submitting this form, I declare that I have completed this form truthfully and I declare that I have informed the correct official(s) of my employing organisation of this submission.

[ ]  I hereby declare that the obligatory letter(s) of commitment of the other consortium partner(s) has/have been uploaded separately.

[ ]  I hereby declare that the application is checked according to **Appendix G**.

Name:

Place:

Date:

Please note: Information provided in relation to this application will be treated confidentially by FORESIGHT Program Group and Health~Holland. Health~Holland has to inform the Netherlands Enterprise Agency (RVO) on the participants of the project and the in cash and in kind contribution of the consortium partners, in order to claim the requested PPP Subsidy. RVO will also treat this information confidentially. Upon granting, the project coordinator will receive a request to provide a project profile, including a summary of the project and other basic project details (see Appendix F) that will be published on the Health~Holland [website](https://www.health-holland.com/project) and for other communication purposes. Other content of the project will not be communicated beyond Health~Holland.

Main applicants must submit this TKI-LSH PPP Subsidy application form by e-mail to

foresight@umcg.nl For any questions regarding submission, please send an e-mail to foresight@umcg.nl

Attachments to be uploaded for a complete full proposal submission:

* TKI-LSH **FORESIGHT** Call 2025 budget form.
* Letters of commitment of **all** parties involved, each stating the parties’ in kind and in cash contribution (separately) to the project. Only the main applicant does not need to upload a letter of commitment. See Appendix F for a template of a letter of commitment.
* Signed copy of the consortium agreement and IP settlements agreed upon in this project. If a signed consortium agreement is not yet available, a concept agreement must be submitted. The signed consortium agreement should be delivered no later than 1 February 2026.
* Signed *‘Verklaring geen onderneming in moeilijkheden’* for every SME that applies for PPP Subsidy. Template to be downloaded from [RVO - Verklaring Geen Onderneming in Moeilijkheden](https://www.rvo.nl/sites/default/files/2023-03/230322-Verklaring-geen-onderneming-in-moeilijkheden-v1.pdf)

**Appendix A: Definition of enterprise**

*English*

According to established case law from the European Court of Justice, an enterprise is any unit that carries out economic activity irrespective of its legal status and manner of funding.

In this regard, the following points are important:

* The legal status (e.g. a private company or a foundation) of the entity is not important;
* A for-profit status is not required, competition on the market is sufficient (economic activities). This means that the entity participates in economic dealings and that there is business funding. Business funding means that the funding cannot consist entirely of grants, gifts and endowments. A turnover needs to be made and there has to be income from economic activity;
* An entity that carries out both economic and non-economic activities will only be designated as an enterprise with respect to the economic activities;
* The European Court of Justice has further determined that entities that (legally or de facto) fall under the authority of the same main entity should be viewed as a single enterprise;
* Having a Dutch ANBI or charitable status (serving the common interest, no profit-making status, 90% rule) means that such an entity with ANBI status cannot also be an enterprise. That is because an entity with ANBI status enjoys fiscal advantages that a business does not enjoy.

With respect to economic activity, the following aspects are, amongst others, considered in line with the Dutch Tax and Customs Administration:

* Registration with the Dutch Chamber of Commerce (KvK);
* Having a Dutch VAT (BTW) number and/or corporate income tax (VPB) number;
* Goods and/or services are delivered;
* The remuneration received for these is more than symbolic;
* The entity participates in the economic arena and enjoys income from this.

*Nederlands*

Volgens vaste rechtspraak van het Europees Hof van Justitie is een onderneming elke eenheid die een economische activiteit uitvoert ongeacht haar rechtsvorm en wijze van financiering.

Hierbij zijn de navolgende punten van belang:

* De juridische status (b.v. BV of een stichting) van de eenheid is niet van belang;
* Er is géén winstoogmerk vereist, concurrentie op de markt is voldoende (economische activiteiten). Dit houdt in dat er wordt deelgenomen aan economisch verkeer en er ondernemingsfinanciering plaatsvindt. Ondernemingsfinanciering betekent dat de financiering niet volledig kan bestaan uit subsidies, giften en schenkingen. Er zal omzet en inkomsten uit economische activiteit moeten plaatsvinden;
* Een eenheid die zowel economische als niet economische activiteiten verricht, wordt alleen met betrekking tot de economische activiteiten aangemerkt als onderneming;
* Het EU Hof van Justitie heeft verder bepaald dat entiteiten die (juridisch of feitelijk) onder de zeggenschap staan van dezelfde entiteit, als één onderneming dienen te worden beschouwd.
* Het hebben van een ANBI-status (algemeen belang dienen, geen winstoogmerk, 90% regel) sluit uit dat een entiteit met ANBI-status ook een onderneming is. Een entiteit met ANBI-status geniet namelijk fiscale voordelen welke een onderneming niet heeft.

Bij economische activiteit wordt, in lijn met de Belastingdienst, onder andere gekeken naar:

* Inschrijving KVK;
* Het hebben van een BTW-nummer en/of VPB-nummer;
* Er worden goederen en/of diensten geleverd;
* Hier staat een meer dan symbolische vergoeding tegenover;
* Men neemt deel aan het economisch verkeer en daar komen inkomsten uit.

**Appendix B: European Commission Recommendation 2003/361/EC regarding SME definition**

1. **Micro-enterprises** are defined as enterpris­es that employ fewer than 10 persons and whose annual turnover or annual balance sheet total does not exceed EUR 2 million.
2. **Small enterprises** are defined as enterpris­es that employ fewer than 50 persons and whose annual turnover or annual balance sheet total does not exceed EUR 10 million.
3.
4. **Medium-sized enterprises** are defined as enterprises that employ fewer than 250 per­sons and either have an annual turnover that does not exceed EUR 50 million, or an annual balance sheet not exceeding EUR 43 million.

For more details ‘The revised User Guide to the SME definition’ can be downloaded [here](https://ec.europa.eu/docsroom/documents/42921).

Or use the European [SME Wizard](https://ec.europa.eu/growth/tools-databases/SME-Wizard/smeq.do;SME_SESSION_ID=O7sad7FQJ5Yv57HLXygn8qU6Ru3fbfplFT6I0g0MuPKEcCyss4su!-1930018156?execution=e1s1)*.*

**Appendix C: Conflict of Interest**

*This Appendix is also available in Dutch and can be requested by sending an email to foresight@umcg.nl*

According to Articles 29.d and 29.c of the Framework, applicable to the PPP Subsidy regulation, research organisations are to receive a remuneration equivalent to the market price for the intellectual property rights arising from their activities during the course of a project. The absence or inadequacy of agreements pertaining to a remuneration based on the market price, leads to the indirect granting of state aid to the participating private parties.

‘A remuneration equivalent to the market price’ creates a best-effort obligation between the parties involved. It means that the research organization and the participating private parties must make an effort to negotiate this remuneration on so-called ‘arm’s length’ terms. Arm’s length conditions mean that the terms of the remuneration do not deviate from those which would be agreed upon in a private setting, between independent parties. Any transaction resulting from an open, transparent and non-discriminatory procedure will be deemed to comply with the arm’s length procedure.

Every project has the potential for a conflict of interest between the research organization and one or more private companies. A conflict of interest can exist on a personal level or on an organizational level. The presence of a conflict of interest means that the arm’s length conditions are potentially not met. Promptly upon identification of an objective conflict of interest, the consortium and FORESIGHT Program Group, and Health~Holland should be notified. A pertinent example is when the director of a participating company, also has an employment relationship with the participating research organization.

Potential COI kan arise in multiple ways, including but not limited to:

*Individual potential COI*

* Does the Principal Investigator in the Project have any financial interest in (one of) the industrial participant(s)? If so, how many shares, options and/or other financial benefits do you (or your relatives) have rights to?
* Does any other Institutional investigator involved in the Project have any financial interest in the industrial particpant(s)? If so, how many shares, options and/or benefits do you (or your relatives) have rights to?

Examples of financial interest may be: the PI or its direct family member have shares, options and/or other participation in any of the Industrial participant(s); the PI receive benefits from patent applications licensed to the Industrial participant(s) or is an inventor listed in any patent application licensed or filed by the industrial participant(s) directly or indirectly related to the subject matter of the Project application.

* In the last 12 months, did any commercial entity or any of the entities that are participating in the Project paid for or reimbursed you (or your employer) for consulting services, salaries or otherwise? If, so does such payments exceed €10.000 per year? If so, will the company benefit from the outcome of the Project?

*Institutional potential CoI*

To the best of your or your Consortium Partners’ knowledge

* Are any of the Consortium Partners in the Project affiliated or associated with another Consortium Partner in the Project? If so, how?
* Does any Consortium Partner have directly or indirectly any shares, options and/or any other participation in another Consortium Partners despite of not being an affiliated entity? If so, how many shares, options and/or participations?
* Or, if the financial interest as stated in the two points above does not apply, would a Consortium Partner exercise any control on any of the other Consortium Partners’ decision making? If so, how?
* In the last 12 months, did any commercial entity or any of the entities that would be a Private partner in the Project paid for or reimbursed any sponsored research or services to the Research Organization(s) to the same research group(s) involved in the Project? If, so does such payments exceed €10.000 per year? If so, will the company benefit from outcome of the Project?

The FORESIGHT Program Group and Health~Holland will not subjectively assess the conflict of interest. The FORESIGHT Program Group and Health~Holland will assess whether the performance of the consortium will be hindered or compromised by the existence of such potential conflict of interest. The FORESIGHT Program Group and Health~Holland will therefore require full transparency if and when an objective conflict of interest arises or is likely to arise. ‘Objective’ means that potentially, a conflict of interest can occur, regardless of whether a party or person can derive any benefit or disadvantage from it.

It is up to the parties concerned – and in particular the directors of the participating companies – to recognize, interpret and report such an objective conflict of interest. This obligation to report may already exist at the time of the application being made. And thus, a notification should be made upon submission of the application.

Such a notification must be accompanied by the response to the following questions:

* What are the motivations to indicate the presence of a conflict of interest?
* Has the director concerned weighed up the interests?
* Has the potential conflict of interest been adequately addressed?
* Is there a transparent procedure in place to ensure that the director can abstain from involvement in certain decisions (which may involve a conflict of interest)?
* How are the arm’s length conditions adequately met?
* Has the director provided for the involvement of other researchers who can make these decisions without bias?
* Can the director involve his or her fellow director(s) in the decision-making process and is it possible in the management relationship for the director concerned to abstain from taking management decisions (four eyes principle)?

The duty to provide adequate answers to the above questions rests exclusively with the consortium parties involved. This means that the consortium parties involved have the duty to assess whether and to what extent the potential conflicting of interest has been adequately addressed and whether they are satisfied with the precautionary measures that the director(s) concerned have taken.

If, as a result of a conflict of interest, situations occur that violate the arm’s length conditions, the (consortium) parties involved are liable for the resulting damage. Such damage may include the consequences of establishing that indirect state aid has been granted to one or more participating undertakings.

For the sake of completeness, The FORESIGHT Program Group and Health~Holland recommends involving legal support from the consortium partners, preferably from the research organization, in order to adequately address a potential conflict of interest.

**Appendix D:** **Definitions of the three types of research[[4]](#footnote-5)**

**Fundamental research** means experimental or theoretical work undertaken primarily to acquire new knowledge of the underlying foundations of phenomena and observable facts, without any direct commercial application or use in view.

**Industrial research** means the planned research or critical investigation aimed at the acquisition of new knowledge and skills for developing new products, processes or services or for bringing about a significant improvement in existing products, processes or services. It comprises the creation of components parts of complex systems, and may include the construction of prototypes in a laboratory environment or in an environment with simulated interfaces to existing systems as

well as of pilot lines, when necessary for the industrial research and notably for generic technology validation.

**Experimental development** means acquiring, combining, shaping and using existing scientific, technological, business and other relevant knowledge and skills with the aim of developing new or improved products, processes or services. This may also include, for example, activities aiming at the conceptual definition, planning and documentation of new products, processes or services. Experimental development may comprise prototyping, demonstrating, piloting, testing and validation of new or improved products, processes or services in environments representative of real life operating conditions where the primary objective is to make further technical improvements on products, processes or services that are not substantially set. This may include the development of a commercially usable prototype or pilot which is necessarily the final commercial product and which is too expensive to produce for it to be used only for demonstration and validation purposes. Experimental development does not include routine or periodic changes

made to existing products, production lines, manufacturing processes, services and other operations in progress, even if those changes may represent improvements.

**Appendix E: Technology Readiness Levels**

|  |  |
| --- | --- |
| **TRL** | **Definition** |
| TRL 1 | Basic principles observed |
| TRL 2 | Technology concept formulated |
| TRL 3 | Experimental proof of concept |
| TRL 4 | Technology validated in lab |
| TRL 5 | Technology validated in relevant environment (industrially relevant environment in the case of key enabling technologies) |
| TRL 6 | Technology demonstrated in relevant environment (industrially relevant environment in the case of key enabling technologies) |
| TRL 7 | System prototype demonstration in operational environment |
| TRL 8 | System complete and qualified |
| TRL 9 | Actual system proven in operational environment (competitive manufacturing in the case of key enabling technologies; or in space) |

**Appendix F:** **Template Letter of Commitment**

***LETTER OF COMMITMENT***

*for the*

***[name of] PROJECT***

Dear FORESIGHT Program Group,

I, [first name and family name], in my capacity of [position in the organisation (has to be a duly authorised person)] at [name legal entity] hereby confirm that [legal entity] is committed to contribute to the [project name] project under the FORESIGHT program, on the condition that Stichting LSH-TKI grants the FORESIGHT PPP Subsidy as applied for by the main applicant, [first name and family name], [position] at [name research organisation].

[Name legal entity] is aware that it is mandatory for the consortium to use the most recent updated version of the model consortium agreement of Health~Holland. [Name legal entity] is aware that only minimal non-essential changes to this template are permitted and agrees to the content of the model consortium agreement regarding Foreground and intellectual property.

[Name legal entity] will contribute € [•] in cash towards the project costs in accordance with the budget in the project proposal and budget form.

[Name legal entity] will provide an in-kind contribution of [description of the contribution], representing a monetary value of € [•] and further detailed in the project proposal and budget form.

Yours sincerely,

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Name:

Position:

Date:

**Appendix G: Checklist application form**

[ ]  The consortium must consist of at least one research organisation and one for-profit enterprise.

[ ]  The main applicant is located in the Netherlands.

[ ]  The project meets the requirement for the maximum project duration **(48** months).

Projects must be concluded at latest by 30 September 2030.

[ ]  For the use of the available FORESIGHT PPS subsidy for 2025 (under the Health Holland Program period 1 January 2025-31 December 2030), projects must be concluded at latest by 30 September 2030. This means that, the latest starting dates of projects are:

* + - For 4-year projects: 1 October 2026
		- For 3-year projects: 1 October 2027
		- For 2-year projects: 1 October 2028

[ ]  The chamber of commerce number or equivalent is listed for all consortium partners.

[ ]  Effective collaboration takes place. This means, for example, that the project is realised at joint cost and risk.

[ ]  The project consists of industrial research, experimental development, or a combination thereof (TRL 4 – 7). Projects at lower TRL levels (TRL<4, fundamental research) can apply but have a lower chance of being awarded.

[ ]  All consortium partners should at least incur payroll costs.

[ ]  All consortium partners should make an *in kind* contribution.

[ ]  Research organisations may finance a maximum of 70% of their costs (e.g. man hours, consumables and the use of equipment etc.) with PPP subsidy in the case of fundamental/industrial research and a maximum of 60% of their costs in the case of experimental development.

[ ]  Dutch SMEs may finance a maximum of 60% of their costs (e.g. man hours, consumables and the use of equipment etc.) with PPP subsidy in the case of fundamental/industrial research and a maximum of 40% of their costs in the case of experimental development.

[ ]  The research organisation(s) must contribute at least 10% of the total project costs.

[ ]  Depending on the type of research the enterprise(s) must contribute at least 15% in case of fundamental/industrial research to 30% in case of experimental development of the total project costs.

[ ]  All parties, with the exception of the main applicant, must submit a letter of commitment using the template provided; a letter of intent is not sufficient.

[ ]  The consortium must submit an (unsigned) draft consortium agreement using the mandatory Health~Holland template; a blank format is not sufficient.

[ ]  All SME’s that apply for PPP Subsidy must submit a signed version of *‘Verklaring geen onderneming in moeilijkheden’*

[ ]  The consortium is aware that in case the project is awarded the PPP Subsidy, the consortium agreement should be completed (after approval of the final version and signed by **1 February 2026.**

[ ]  The budgeted costs are directly related to the R&D activities, and do not include non-eligible costs, for example: bench fee costs, travel within the Netherlands, supporting/project management tasks that are not directly related to the project’s R&D activities.

[ ]  All questions on the application form are answered.

[ ]  The right versions of the application form, budget form and consortium agreement specific to the **FORESIGHT** Call **2025** have been used.

**Appendix G: Checklist application form**

**Appendix 1: Definitions of Social theme, Missions, and documents to consult related to Dutch strategies for Life Sciences and Health sector, growth markets and priority key technologies.**

*Social theme 'Health & Care'*

In the spring of 2019, the Ministry of Health, Welfare, and Sport (VWS) established five missions for the social theme of Health & Care. One central mission and four focused missions. The central mission focuses on living in good health longer while reducing health disparities between people of high and low socioeconomic status. The other four missions contribute to this central mission through changes in the living environment, providing more care in the right place, and better prospects for people with chronic diseases and dementia. The missions have a time horizon extending to 2040. In the fall of 2023, a fifth focused mission was added, aimed at societally disruptive health threats. The Knowledge and Innovation Agenda 2024-2027 (KIA) describes the ambitions and goals of the health and care missions within the field of public-private partnerships. As the lead party, the Top Sector LSH has prepared this KIA together with many public and private stakeholders. The process involves building on a powerful ecosystem of public-private partnerships that has been established in recent years. Many of these stakeholders have committed themselves to the objectives of the KIA by means of in mind, in kind, and in cash contributions to the Knowledge and Innovation Covenant (KIC).

*Missions of the Top Sector LSH*

* Central Mission:By 2040, everyone in the Netherlands will live at least five years longer in good health, while the health inequalities between the lowest and highest socio-economic groups will have decreased by 30%.
* Mission I: By 2040, the disease burden resulting from an unhealthy lifestyle and living environment will have decreased by 30%.
* Mission II: By 2030, the extent of care provided to people within their own living environment will be 50% more than today, or such care will be provided 50% more frequently than at present.
* Mission III: By 2030, the proportion of people with a chronic disease or lifelong disability who can play an active role in society according to their wishes and capabilities will have increased by 25%.
* Mission IV: By 2030, the quality of life for people with dementia will have improved by 25%.
* Mission V: By 2035, the population is better protected from socially disruptive health threats.

**Specific Growth Markets identified: Medical technology and Innovative and high-quality molecules in the biotech sector.**

Specific key technologies of attention are: 1) Biomolecular and cell technologies; 2) Imaging Technologies; 3) Artificial intelligence and data science

*Guidance documents*

* Missions Health & Care document 2024-2027: [Missies Gezondheid & Zorg 2024 – 2027 (health-holland.com)](https://www.health-holland.com/sites/default/files/downloads/Missiedocument%20Gezondheid%20en%20Zorg%202024-2027.pdf)
* Health~Holland publication on Health & Care 2030: [Van toekomstbeelden naar toekomstgerichte actie voor noodzakelijke impact | Health~Holland (health-holland.com)](https://www.health-holland.com/en/publications/useful-documents/kia)
* Knowledge and Innovation Agenda 2024-2027: [Kennis- en Innovatieagenda Gezondheid & Zorg 2024-2027 (fliphtml5.com)](https://online.fliphtml5.com/gedjp/iwgv/#p=1)
* Knowledge and Innovation Convenant 2024-2027 [Knowledge and Innovation Covenant 2024-2027 | Covenant | Rijksoverheid.nl](https://www.rijksoverheid.nl/documenten/convenanten/2023/11/03/kennis-en-innovatieconvenant-2024-2027)
* Overview Growth Markets LSH Sector Netherlands [promising growth markets](https://www.rijksoverheid.nl/documenten/rapporten/2023/12/05/dialogic-seo-groeimarkten-voor-nederland)
* Ten priority key technologies where the Dutch knowledge field and industry can make a positive impact and which are essential for the future. [Knowledge and Innovation Agenda for Key Enabling Technologies](https://hollandhightech.nl/hoe-we-helpen/kennis-en-innovatieagenda-s/kia-sleuteltechnologieen) (KIA-ST) and [Key Methodologies research agenda](https://kems.clicknl.nl/) is part of the KIA-ST.
* Key methodologies (KEM) toolbox  for the realisation of social innovation in the form of models, strategies, processes and tools. [KEM website](https://kems.nl/)
* HI-NL Round table service, provided by Health~Holland: [About | Health Innovation Netherlands](https://www.healthinnovation.nl/about)

**Appendix 4: Examples of ineligible costs and third party costs**

The following are examples of ineligible costs*.* Therefore, these costs should not be entered on the budget form*.*

* Applying for and maintaining patents (costs for patents purchased on arm's length terms from or licensed from outside sources are eligible);
* Audit, Auditor’s statement;
* Bench fee (note: costs for consumables/material costs are eligible);
* Travel within the Netherlands (domestic travels);
* Support staff not directly related to the R&D activities, such as project controller, business developer, and administrative officer;
* Preparation of a business case;
* Costs related to implementation of the developed innovation;
* Carrying out effectiveness studies (Health Technology Assessment, HTA);
* Non-scientific dissemination. However, scientific dissemination, including attending a scientific congress or publishing a scientific article, is eligible*.*
* Project management tasks not directly related to the specific R&D activities, such as escalation to a steering committee, preparing a risk management model, preparing reports to meet funding obligations, and administrative accountability. Project management tasks related directly to the R&D activities (e.g., discussions with staff, analyzing technical risks, preparing research reports, and preparing specifications) are eligible.

*Costs due to third parties*

If part of the activities are outsourced, these costs due to third parties can be allocated to the project and entered on the budget form. It must be ensured that the costs owed to third parties are in proportion to the rest of the budget. If this cost item is very high, this can have an impact and be included in the assessment of the project.

1. In case of a potential conflict of interest (at a personal or organizational level), please disclose the situation following Appendix C under question 4. [↑](#footnote-ref-2)
2. Note: non-scientific dissemination costs are not eligible for funding withing the PPP Subsidy program, therefore, costs relating to this dissemination may not be incurred on the official budget form. [↑](#footnote-ref-3)
3. For more information please consult this [link](https://www.dtls.nl/fair-data/fair-data/). [↑](#footnote-ref-4)
4. In case of drug development, pre-clinical research in animals falls within the research category ‘industrial research’. In principle, the clinical phases 1 and 2 fall within the research category ‘experimental development’. Phase 3 clinical trials (and beyond) are seen as competitive development and fall outside the scope of the PPP Subsidy Regulation. [↑](#footnote-ref-5)